187
Participants
Start Date
August 9, 2006
Primary Completion Date
March 3, 2009
Study Completion Date
April 7, 2009
seliciclib
1200 mg bid x 3 days every 2 weeks
placebo
1200 mg bid x 3 days every 2 weeks
Columbia Presbyterian Medical Center, New York
University of Pittsburg Cancer Institute, Pittsburgh
Penn State Milton S. Hershey Medical Center, Hershey
University of Maryland, Greenebaun Cancer Center, Baltimore
Danville Hematology Oncology, Danville
Pasco Hernando Oncology, New Port Richey
Vanderbilt University Medical Center, Nashville
The Family Cancer Center, Collierville
Rush University Medical Center, Chicago
The University of Chicago, Chicago
Nebraska Medical Center, Omaha
Center for Oncology Research and Treatment, Dallas
East Texas Medical Center, Tyler
Southwest Regional Cancer Center, Austin
Arizona Cancer Center, Tucson
New Mexico Oncology Hematology Consultants, Albuquerque
Nevada Cancer Research Foundation, Las Vegas
VA Sierra Nevada Health Care System, Reno
Pacific Coast Hematology Oncology Group, Fountain Valley
Dana Farber Cancer Institute, Boston
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
INDUSTRY